BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28584138)

  • 1. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
    Le A; Farmakiotis D; Tarrand JJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
    Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
    Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.
    Puig-Asensio M; Fernández-Ruiz M; Aguado JM; Merino P; Lora-Pablos D; Guinea J; Martín-Dávila P; Cuenca-Estrella M; Almirante B
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3291-300. PubMed ID: 26976872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
    Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
    Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.
    Eschenauer GA; Carver PL; Lin SW; Klinker KP; Chen YC; Potoski BA; Shields RK; Clancy CJ; Nguyen MH; Lam SW
    J Antimicrob Chemother; 2013 Apr; 68(4):922-6. PubMed ID: 23212115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
    Doğan Ö; Yeşilkaya A; Menekşe Ş; Güler Ö; Karakoç Ç; Çınar G; Kapmaz M; Aydın M; Keske Ş; Şahin S; Hacıseyitoğlu D; Yalçın D; Tekin S; Ataç N; Albayrak Ö; Aksu ED; Can F; Ergönül Ö
    Int J Antimicrob Agents; 2020 Jul; 56(1):105992. PubMed ID: 32335275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.
    Bizerra FC; Jimenez-Ortigosa C; Souza AC; Breda GL; Queiroz-Telles F; Perlin DS; Colombo AL
    Antimicrob Agents Chemother; 2014; 58(4):2438-40. PubMed ID: 24468776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis.
    Cuervo G; Garcia-Vidal C; Puig-Asensio M; Vena A; Meije Y; Fernández-Ruiz M; González-Barberá E; Blanco-Vidal MJ; Manzur A; Cardozo C; Gudiol C; Montejo JM; Pemán J; Ayats J; Aguado JM; Muñoz P; Marco F; Almirante B; Carratalà J;
    Clin Infect Dis; 2017 May; 64(10):1374-1379. PubMed ID: 28329281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
    Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
    J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
    Wang H; Xu YC; Hsueh PR
    Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azole resistance of Candida glabrata in a case of recurrent fungemia.
    Posteraro B; Tumbarello M; La Sorda M; Spanu T; Trecarichi EM; De Bernardis F; Scoppettuolo G; Sanguinetti M; Fadda G
    J Clin Microbiol; 2006 Aug; 44(8):3046-7. PubMed ID: 16891541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and susceptibility of Nakaseomyces (formerly Candida) glabrata bloodstream isolates from hospitalised adults in South Africa.
    Naicker SD; Shuping L; Zulu TG; Mpembe RS; Mhlanga M; Tsotetsi EM; Maphanga TG; Govender NP;
    Med Mycol; 2023 Jun; 61(6):. PubMed ID: 37336590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution and drug susceptibilities of Candida species causing candidemia from a medical center in central Taiwan.
    Chang TP; Ho MW; Yang YL; Lo PC; Lin PS; Wang AH; Lo HJ
    J Infect Chemother; 2013 Dec; 19(6):1065-71. PubMed ID: 23732308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
    Garnacho-Montero J; Díaz-Martín A; Cantón-Bulnes L; Ramírez P; Sierra R; Arias-Verdú D; Rodríguez-Delgado M; Loza-Vázquez A; Rodriguez-Gomez J; Gordón M; Estella Á; García-Garmendia JL
    Crit Care Med; 2018 Mar; 46(3):384-393. PubMed ID: 29189345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of mortality between echinocandins and polyenes for an initial treatment of candidemia: A systematic review and meta-analysis.
    Kato H; Hagihara M; Shibata Y; Asai N; Yamagishi Y; Iwamoto T; Mikamo H
    J Infect Chemother; 2021 Nov; 27(11):1562-1570. PubMed ID: 34217605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
    Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
    J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida glabrata--unique features and challenges in the clinical management of invasive infections.
    Glöckner A; Cornely OA
    Mycoses; 2015 Aug; 58(8):445-50. PubMed ID: 26207423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for
    Wright WF; Bejou N; Shields RK; Marr K; McCarty TP; Pappas PG
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31345844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
    Coste AT; Kritikos A; Li J; Khanna N; Goldenberger D; Garzoni C; Zehnder C; Boggian K; Neofytos D; Riat A; Bachmann D; Sanglard D; Lamoth F;
    Infection; 2020 Oct; 48(5):761-766. PubMed ID: 32661647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.